Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference
Kaleido Biosciences (Nasdaq: KLDO) will have CEO Dan Menichella present at the JMP Securities Life Sciences Conference on June 17, 2021, at 4 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kaleido Biosciences (Nasdaq: KLDO) will have CEO Dan Menichella present at the JMP Securities Life Sciences Conference on June 17, 2021, at 4 PM ET. This event will focus on Kaleido's innovative approach to microbiome-targeted therapies for disease treatment. Investors can access the live webcast through Kaleido’s website, with an archived replay available for 90 days post-event. The company aims to transform healthcare through its proprietary Microbiome Metabolic Therapies (MMT™), addressing significant unmet patient needs.
Details
News Market Reaction – KLDO
The recorded move for KLDO in the trading session of this news was +3.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will deliver a corporate presentation at the JMP Securities Life Sciences Conference at 4PM ET on Thursday, June 17.
The webcast of the presentation will be made available in the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be available for 90 days following the event.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Contacts:
Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com
Investors
Mike Biega
Solebury Trout
617-221-9660
mbiega@soleburytrout.com
Media
Amy Bonanno
Solebury Trout
914-450-0349
abonanno@soleburytrout.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.